Filtros de búsqueda

Lista de obras de

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

artículo científico publicado en 2016

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme ⬇️

artículo científico publicado el 11 de enero de 2011

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population

artículo científico publicado en 2017

A novel method for volumetric MRI response assessment of enhancing brain tumors

artículo científico publicado en 2011

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

scientific article published on 20 May 2020

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

artículo científico publicado en 2011

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

artículo científico publicado en 2011

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

artículo científico publicado en 2012

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

artículo científico publicado en 2008

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

artículo científico publicado en 2011

ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

artículo científico publicado en 2018

ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)

ACTR-64. PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)

AT-19SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.

artículo científico publicado en 2014

AT-20SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).

artículo científico publicado en 2014

AT-21FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).

artículo científico publicado en 2014

AT-22PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION

AT-46VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL

AT-48A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE

ATCT-01PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG).

artículo científico publicado en 2015

ATCT-13BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION: A PHASE II TRIAL.

artículo científico publicado en 2015

ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS

artículo científico publicado en 2017

ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)

Abstracts

article by L. Bie et al published 1 April 2013 in Neuro-Oncology

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

artículo científico publicado en 2010

Adjunctive perampanel for glioma-associated epilepsy

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing

artículo científico publicado en 2009

Avastin: more questions than answers. . .

artículo científico publicado en 2011

Bevacizumab and daily temozolomide for recurrent glioblastoma

artículo científico publicado en 2011

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

artículo científico publicado en 2012

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration

artículo científico publicado en 2009

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

artículo científico publicado en 2008

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

artículo científico publicado en 2007

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

artículo científico publicado en 2012

Bevacizumab therapy for glioblastoma: a passionate discussion

artículo científico publicado en 2014

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma

artículo científico publicado en 2011

CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.

artículo científico publicado en 2015

CLIN-NEURO/MEDICAL ONCOLOGY

Chemotherapy and novel therapeutic approaches in malignant glioma

artículo científico publicado en 2005

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population

artículo científico publicado en 2019

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial

artículo científico publicado en 2013

Current available therapies and future directions in the treatment of malignant gliomas.

artículo científico publicado en 2009

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

artículo científico publicado en 2017

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

artículo científico publicado en 2010

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

artículo científico publicado en 2008

Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience

artículo científico publicado en 2005

Everolimus tablets for patients with subependymal giant cell astrocytoma

artículo científico publicado en 2011

Evolutionary conservation of drug action on lipoprotein metabolism-related targets

artículo científico publicado en 2007

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma

artículo científico publicado en 2011

Experience with irinotecan for the treatment of malignant glioma

artículo científico publicado en 2008

Expression patterns of the Drosophila neuropeptide CCHamide-2 and its receptor may suggest hormonal signaling from the gut to the brain

artículo científico publicado en 2013

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

scientific article published on 01 April 2008

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma ⬇️

artículo científico publicado el 10 de diciembre de 2010

HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN

HOUT-19. TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS

artículo científico publicado en 2018

IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA.

artículo científico publicado en 2015

IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).

artículo científico publicado en 2015

IMMU-21. TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN

IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA

artículo científico publicado en 2014

IT-34PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).

artículo científico publicado en 2014

Imaging descriptors improve the predictive power of survival models for glioblastoma patients

artículo científico publicado en 2013

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma

artículo científico publicado en 2008

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

artículo científico publicado en 2014

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

artículo científico publicado en 2019

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

artículo científico publicado en 2007

Introduction of our new associate editor

artículo científico publicado en 2014

MEDICAL AND NEURO-ONCOLOGY

artículo científico publicado en 2011

MS-19LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS.

artículo científico publicado en 2014

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

artículo científico publicado en 2015

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

artículo científico publicado en 2009

Molecularly targeted therapy for malignant glioma

artículo científico publicado en 2007

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

artículo científico publicado en 2011

NEURO/MEDICAL ONCOLOGY

Neuro-oncology: Glioblastoma--community adjusts to new standard of care

artículo científico publicado en 2012

Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?

artículo científico publicado en 2015

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results

artículo científico publicado en 2006

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma

scientific article published on 18 May 2013

ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN RECURRENT GLIOBLASTOMA (GBM): FIRST PHASE I CLINICAL TRIAL EVALUATING THE INTRATUMORAL ADMINISTRATION.

artículo científico publicado en 2014

ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF GLIOBLASTOMA.

artículo científico publicado en 2014

ONGOING CLINICAL TRIALS

article

Oncolytic polio virotherapy of cancer

artículo científico publicado en 2014

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

artículo científico publicado en 2011

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

artículo científico publicado en 2009

PALL-02. PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS

PALL-10. INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series

artículo científico publicado en 2020

Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort

artículo científico publicado en 2019

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas

artículo científico publicado en 2015

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

artículo científico publicado en 2012

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

artículo científico publicado en 2006

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

artículo científico publicado en 2009

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

artículo científico publicado en 2011

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

artículo científico publicado en 2009

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

artículo científico publicado en 2009

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

artículo científico publicado en 2011

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

artículo científico publicado en 2005

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

artículo científico publicado en 2009

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

artículo científico publicado en 2005

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

artículo científico publicado en 2017

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

artículo científico publicado en 2017

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

artículo científico publicado en 2018

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

artículo científico publicado en 2015

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

artículo científico publicado en 2006

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

artículo científico publicado en 2012

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

artículo científico publicado en 2011

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

artículo científico publicado en 2017

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

artículo científico publicado en 2017

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

artículo científico publicado en 2011

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

artículo científico publicado en 2007

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

artículo científico publicado en 2005

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

artículo científico publicado en 2010

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

artículo científico publicado en 2016

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme

artículo científico publicado en 2009

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

artículo científico publicado en 2010

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

artículo científico publicado en 2007

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

artículo científico publicado en 2009

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

artículo científico publicado en 2009

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

artículo científico publicado en 2013

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis

publication published on 21 September 2021

QL-20PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA.

artículo científico publicado en 2014

QL-21SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS.

artículo científico publicado en 2014

QLIF-05. A SINGLE INSTITUTION’S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA

article published in 2017

QLIF-22. MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB

QLIF-34. PILOT STUDY TO DESCRIBE THE TRAJECTORY OF SYMPTOMS AND ADAPTIVE STRATEGIES OF ADULTS LIVING WITH LOW GRADE GLIOMAS (LGG)

article by Mary Lou Affronti et al published 6 November 2017 in Neuro-Oncology

QOL-19PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN.

artículo científico publicado en 2015

QOL-20LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY.

artículo científico publicado en 2015

QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION.

artículo científico publicado en 2015

QOLP-13. PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS

RARE-16. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS

RARE-25. A RETROSPECTIVE, SINGLE INSTITUTION STUDY OF CENTRAL NEUROCYTOMA (2004-2016): SURVIVAL, TREATMENT, AND SUPPORTIVE CARE

RARE-36. PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

article published in 2017

RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL

RTRB-04STEREOTACTIC RADIOSURGERY FOR RECURRENT HIGH-GRADE GLIOMAS: PATIENT SELECTION AND THE ROLE OF BEVACIZUMAB.

artículo científico publicado en 2015

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

scientific article published on 22 August 2019

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

artículo científico publicado en 2018

Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme

artículo científico publicado en 2009

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

artículo científico publicado en 2020

SM-02LEVETIRACETAM USAGE IN POST-OPERATIVE SEIZURE MANAGEMENT IN MALIGNANT GLIOMA

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas

artículo científico publicado en 2011

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

artículo científico publicado en 2008

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

artículo científico publicado en 2006

Second primary cancers in long-term survivors of glioblastoma

scientific article published on 04 February 2019

Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide

artículo científico publicado en 2014

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

artículo científico publicado en 2018

Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor

artículo científico publicado en 2004

Temozolomide in children with progressive low-grade glioma

artículo científico publicado en 2007

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

artículo científico publicado en 2015

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

artículo científico publicado en 2011

The emerging role of anti-angiogenic therapy for malignant glioma

artículo científico publicado en 2008

The role of chemotherapy in the treatment of central neurocytoma

artículo científico publicado en 2019

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients

artículo científico publicado en 2009

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

scientific article published on January 2008

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

artículo científico publicado en 2010

Vaccine Therapy, Oncolytic Viruses, and Gliomas

artículo científico publicado en 2016

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

artículo científico publicado en 2021

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

artículo científico publicado en 2015

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda